Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 21157382)

1.

Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.

Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, Perry A, Gutmann DH.

J Neuropathol Exp Neurol. 2011 Jan;70(1):1-12. doi: 10.1097/NEN.0b013e3182018f1c.

2.

DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.

Menghi F, Orzan FN, Eoli M, Farinotti M, Maderna E, Pisati F, Bianchessi D, Valletta L, Lodrini S, Galli G, Anghileri E, Pellegatta S, Pollo B, Finocchiaro G.

Oncologist. 2011;16(10):1440-50. doi: 10.1634/theoncologist.2010-0249. Epub 2011 Sep 23.

3.

Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.

Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P.

Int J Cancer. 2005 Mar 20;114(2):249-56.

PMID:
15540215
4.

Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.

Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A.

Cancer Res. 2005 Aug 15;65(16):7121-6.

5.

Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.

Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A.

Int J Oncol. 2009 Dec;35(6):1395-407.

PMID:
19885562
6.

Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, Perry A.

Am J Pathol. 2002 Aug;161(2):665-72.

7.

Genetic alterations associated with progression and recurrence in meningiomas.

Pérez-Magán E, Campos-Martín Y, Mur P, Fiaño C, Ribalta T, García JF, Rey JA, Rodríguez de Lope A, Mollejo M, Meléndez B.

J Neuropathol Exp Neurol. 2012 Oct;71(10):882-93.

PMID:
22964784
8.

Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B.

Neuro Oncol. 2010 Dec;12(12):1278-90. doi: 10.1093/neuonc/noq081. Epub 2010 Aug 4.

10.

Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.

Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J.

Histol Histopathol. 2010 Mar;25(3):341-9.

PMID:
20054806
11.

Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.

Bie L, Zhao G, Ju Y, Zhang B.

Cancer Genet. 2011 Oct;204(10):536-40. doi: 10.1016/j.cancergen.2011.08.019.

PMID:
22137483
12.

Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.

Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, Helm GA.

Neurosurgery. 2008 Oct;63(4):771-80; discussion 780-1. doi: 10.1227/01.NEU.0000325488.72518.9E.

PMID:
18981889
13.

Gene expression profiling of ErbB receptors and ligands in human meningiomas.

Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, Salmon I, Szijan I.

Cancer Invest. 2009 Jul;27(6):691-8. doi: 10.1080/07357900802709175.

PMID:
19440932
14.

Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.

Trinkaus M, Vranic A, Dolenc VV, Lah TT.

Int J Biol Markers. 2005 Jan-Mar;20(1):50-9.

PMID:
15832773
15.

Methylation markers of malignant potential in meningiomas.

Vengoechea J, Sloan AE, Chen Y, Guan X, Ostrom QT, Kerstetter A, Capella D, Cohen ML, Wolinsky Y, Devine K, Selman W, Barnett GH, Warnick RE, McPherson C, Chiocca EA, Elder JB, Barnholtz-Sloan JS.

J Neurosurg. 2013 Oct;119(4):899-906. doi: 10.3171/2013.7.JNS13311. Epub 2013 Aug 9.

PMID:
23930849
16.

HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas.

Di Vinci A, Brigati C, Casciano I, Banelli B, Borzì L, Forlani A, Ravetti GL, Allemanni G, Melloni I, Zona G, Spaziante R, Merlo DF, Romani M.

Transl Res. 2012 Nov;160(5):355-62. doi: 10.1016/j.trsl.2012.05.007. Epub 2012 Jun 23.

PMID:
22735029
17.

Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression.

Sayagués JM, Tabernero MD, Maíllo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A.

J Neuropathol Exp Neurol. 2006 May;65(5):445-54.

PMID:
16772868
18.

NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.

Buccoliero AM, Castiglione F, R Degl'Innocenti D, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL.

Neuropathology. 2007 Feb;27(1):36-42.

PMID:
17319281
19.

Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.

Serna E, Morales JM, Mata M, Gonzalez-Darder J, San Miguel T, Gil-Benso R, Lopez-Gines C, Cerda-Nicolas M, Monleon D.

PLoS One. 2013 Jun 28;8(6):e67291. doi: 10.1371/journal.pone.0067291. Print 2013.

20.

Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas.

Tabernero MD, Espinosa AB, Maillo A, Rebelo O, Vera JF, Sayagues JM, Merino M, Diaz P, Sousa P, Orfao A.

Oncologist. 2007 Oct;12(10):1225-36.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk